The FDA has granted accelerated approval to amivantamab and hyaluronidase for advanced HNSCC based on the OrigAMI-4 trial.
November 2026 Brief
The FDA assigned an April 9, 2027, PDUFA date to rivoceranib plus camrelizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zanubrutinib Plus Rituximab Receives FDA Priority Review in Frontline MCL
3
How Will Pancreatic, Prostate, and Endometrial Cancer Care Change by 2031?
4
Maintenance Lurbinectedin Raises Stakes of Checkpoint Choice in ES-SCLC
5